Eli Lilly shareholders elected four directors, approved executive compensation and auditor ratification at the 2026 Annual Meeting, but rejected proposals to declassify the board and eliminate supermajority voting.
Key takeaways
Four director nominees elected with strong support: Carolyn Bertozzi (90% For), William Kaelin Jr. (86%), Jon Moeller (95%), David Ricks (92%).
Advisory approval of named executive officer compensation: 731M For vs 30M Against.
Ernst & Young LLP ratified as 2026 independent auditor with 802M For votes.
Proposal to eliminate classified board failed to meet 80% threshold (665M For).
Proposal to remove supermajority voting failed (664M For, short of 80%).
Shareholder proposals for independent board chair and lobbying report rejected.